DOSIsoft Establishes New Entity Focused on Advancing Theranostics Software

DOSIsoft, a prominent provider of dosimetry software, has announced the creation of DOSIsoft Theranostics, a new venture aimed at innovating software solutions for the growing field of theranostics in nuclear medicine. This initiative is set to drive the adoption of personalized nuclear medicine through advanced software capabilities.

DOSIsoft Theranostics will operate as an independent entity, allowing it to focus efforts specifically on theranostics, which merges diagnostic imaging and targeted therapy to tailor treatments to individual patients. With its founding in advance of the SNMMI 2026 Annual Meeting, this new division is poised to enhance clinical practices and industrial applications by building upon DOSIsoft's extensive experience.

The launch underscores the increasing relevance of theranostics as it evolves to support personalized treatment plans across multiple modalities and therapeutic approaches. DOSIsoft Theranostics will leverage its experienced scientific team and cutting-edge software tools to promote clinical innovation and improve the outcomes of radiopharmaceutical therapies.

Central to this initiative is the PLANET® software platform, renowned for its advanced voxel-based dosimetry and multi-modality DICOM interoperability. PLANET® is the foundation of DOSIsoft Theranostics' technology, offering clinicians worldwide a robust system that aligns with diverse clinical workflows. It has received both FDA 510(k) clearance and CE marking, marking its acceptance and integration into top hospitals and academic centers globally.

This development reflects DOSIsoft’s long-term commitment to the theranostics domain. Marc Uszynski, CEO of DOSIsoft, emphasized the importance of creating a specialized organization to foster innovation, partnerships, and application expansion for theranostics on a global scale.

DOSIsoft Theranostics will be displayed at the SNMMI 2026 Meeting, indicating its active engagement within the professional community. This step forward highlights the significant role of theranostics in advancing personalized medicine and offers promising implications for its future integration into routine clinical practice.

For further information about DOSIsoft and its commitments to personalized dosimetry and cancer treatment improvements, visit their official website here.